Epigenetics in prostate cancer treatment

Katelyn Jones, Yanquan Zhang, Yifan Kong, Elia Farah, Ruixin Wang, Chaohao Li, Xinyi Wang, Zhuang Zhuang Zhang, Jianlin Wang, Fengyi Mao, Xiaoqi Liu, Jinghui Liu

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Prostate cancer (PCa) is the most commonly diagnosed malignancy among men, and the progression of this disease results in fewer treatment options available to clinical patients. It highlights the vital necessity for discovering novel therapeutic approaches and expanding the current understanding of molecular mechanisms. Epigenetic alternations such as DNA methylation models and histone modifications have been associated as key drivers in the development and advancement of PCa. Several studies have been conducted and demonstrated that targeting these epigenetic enzymes or regulatory proteins has been strongly associated with the regulation of cancer cell growth. Due to the success rate of these therapeutic routes in pre-clinical settings, many drugs have now advanced to clinical testing, where efficacy will be measured. This review will discuss the role of epigenetic modifications in PCa development and its function in the progression of the disease to resistant forms and introduce therapeutic strategies that have demonstrated successful results as PCa treatment.

Original languageEnglish
Pages (from-to)341-356
Number of pages16
JournalJournal of Translational Genetics and Genomics
Issue number3
StatePublished - 2021

Bibliographical note

Publisher Copyright:
© The Author(s) 2021.


  • Epigenetics
  • prostate cancer
  • prostate cancer treatment

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics


Dive into the research topics of 'Epigenetics in prostate cancer treatment'. Together they form a unique fingerprint.

Cite this